vs
CATALYST PHARMACEUTICALS, INC.（CPRX）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $152.6M、CATALYST PHARMACEUTICALS, INC.の約1.2倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 34.5%、差は13.4%）。CATALYST PHARMACEUTICALS, INC.の前年同期比売上増加率が高い（7.6% vs -21.9%）。過去8四半期でCATALYST PHARMACEUTICALS, INC.の売上複合成長率が高い（24.5% vs -15.4%）
Catalyst Pharmaceuticalsは米国フロリダ州コーラルゲーブルズに本拠を置くバイオ医薬品企業で、希少疾患向け治療薬の開発を事業の核心としています。主力品にランバート・イートン筋無力症候群（LEMS）治療薬のアミファンプリジンリン酸塩（商品名Firdapse）があり、2018年11月のFDA承認により、既存の成人に加え6歳以上の小児LEMS患者への投与も認められました。
CPRX vs RILY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $152.6M | $188.3M |
| 純利益 | $52.7M | $90.3M |
| 粗利率 | 82.9% | 79.5% |
| 営業利益率 | 40.5% | 32.3% |
| 純利益率 | 34.5% | 47.9% |
| 売上前年比 | 7.6% | -21.9% |
| 純利益前年比 | -5.8% | 1710.8% |
| EPS（希薄化後） | $0.40 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $152.6M | $188.3M | ||
| Q3 25 | $148.4M | $215.3M | ||
| Q2 25 | $146.6M | $188.2M | ||
| Q1 25 | $141.4M | $197.2M | ||
| Q4 24 | $141.8M | $241.0M | ||
| Q3 24 | $128.7M | $225.5M | ||
| Q2 24 | $122.7M | $256.0M | ||
| Q1 24 | $98.5M | $263.4M |
| Q4 25 | $52.7M | $90.3M | ||
| Q3 25 | $52.8M | $91.1M | ||
| Q2 25 | $52.1M | $139.5M | ||
| Q1 25 | $56.7M | $-10.0M | ||
| Q4 24 | $55.9M | $-5.6M | ||
| Q3 24 | $43.9M | $-284.4M | ||
| Q2 24 | $40.8M | $-433.6M | ||
| Q1 24 | $23.3M | $-49.2M |
| Q4 25 | 82.9% | 79.5% | ||
| Q3 25 | 84.7% | 83.7% | ||
| Q2 25 | 85.9% | 81.3% | ||
| Q1 25 | 87.3% | 81.4% | ||
| Q4 24 | 84.7% | 79.8% | ||
| Q3 24 | 85.0% | 82.1% | ||
| Q2 24 | 87.4% | 84.5% | ||
| Q1 24 | 87.3% | 85.3% |
| Q4 25 | 40.5% | 32.3% | ||
| Q3 25 | 44.7% | 30.4% | ||
| Q2 25 | 45.2% | 5.7% | ||
| Q1 25 | 44.8% | -31.2% | ||
| Q4 24 | 44.3% | -69.2% | ||
| Q3 24 | 39.6% | -36.4% | ||
| Q2 24 | 44.2% | -90.8% | ||
| Q1 24 | 27.5% | -6.1% |
| Q4 25 | 34.5% | 47.9% | ||
| Q3 25 | 35.6% | 42.3% | ||
| Q2 25 | 35.6% | 74.1% | ||
| Q1 25 | 40.1% | -5.1% | ||
| Q4 24 | 39.4% | -2.3% | ||
| Q3 24 | 34.1% | -126.1% | ||
| Q2 24 | 33.2% | -169.4% | ||
| Q1 24 | 23.6% | -18.7% |
| Q4 25 | $0.40 | $2.78 | ||
| Q3 25 | $0.42 | $2.91 | ||
| Q2 25 | $0.41 | $4.50 | ||
| Q1 25 | $0.45 | $-0.39 | ||
| Q4 24 | $0.44 | $-0.01 | ||
| Q3 24 | $0.35 | $-9.39 | ||
| Q2 24 | $0.33 | $-14.35 | ||
| Q1 24 | $0.19 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $709.2M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $954.3M | $-171.5M |
| 総資産 | $1.1B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $709.2M | $226.6M | ||
| Q3 25 | $689.9M | $184.2M | ||
| Q2 25 | $652.8M | $267.4M | ||
| Q1 25 | $580.7M | $138.3M | ||
| Q4 24 | $517.6M | $146.9M | ||
| Q3 24 | $442.3M | $159.2M | ||
| Q2 24 | $375.7M | $236.9M | ||
| Q1 24 | $310.4M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $954.3M | $-171.5M | ||
| Q3 25 | $920.2M | $-260.5M | ||
| Q2 25 | $856.0M | $-351.7M | ||
| Q1 25 | $794.3M | $-496.8M | ||
| Q4 24 | $727.6M | $-488.2M | ||
| Q3 24 | $660.9M | $-497.6M | ||
| Q2 24 | $608.7M | $-218.3M | ||
| Q1 24 | $561.4M | $228.4M |
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.5B | ||
| Q4 24 | $851.4M | $1.8B | ||
| Q3 24 | $772.0M | $2.2B | ||
| Q2 24 | $706.4M | $3.2B | ||
| Q1 24 | $646.7M | $5.0B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $44.9M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $44.9M | — |
| FCFマージンFCF / 売上 | 29.4% | — |
| 設備投資強度設備投資 / 売上 | 0.0% | — |
| キャッシュ転換率営業CF / 純利益 | 0.85× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $44.9M | $26.2M | ||
| Q3 25 | $32.4M | $-60.6M | ||
| Q2 25 | $71.3M | $-25.6M | ||
| Q1 25 | $60.0M | $184.0K | ||
| Q4 24 | $70.9M | $-2.7M | ||
| Q3 24 | $72.9M | $19.5M | ||
| Q2 24 | $64.1M | $111.5M | ||
| Q1 24 | $31.9M | $135.4M |
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 0.85× | 0.29× | ||
| Q3 25 | 0.61× | -0.66× | ||
| Q2 25 | 1.37× | -0.18× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
